
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is a global science and technology company operating in the biotechnology, life sciences, and diagnostics sectors. The company has a solid track record of organic growth and strategic acquisitions, and their bioprocessing segment, which represents more than 25% of revenue, is showing strong demand trends. With a culture of continuous improvement and a focus on sustainability, Danaher is well positioned for long-term success in their key markets.
Bears say
Danaher is facing difficulties in its respiratory testing business as it has seen a decrease in demand for its molecular diagnostics products, resulting in a significant portion of its revenue being reliant on this seasonal and variable market. Additionally, its current valuation at a 15x P/E multiple, which is consistent with its large medtech competitors, reflects a lack of premium awarded to its Tools segment. Despite positive signs of growth in its biotechnology and diagnostic segments, Danaher's growth rebound may take longer to occur, resulting in a downside risk for its stock.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares